Lee S H, Chiu H, Rinderknecht E, Sabo W, Stebbing N
Cancer Res. 1983 Sep;43(9):4172-5.
A highly purified hybrid human leukocyte interferon, IFN-alpha AD, produced in Escherichia coli, has been used to define optimum treatment conditions for L1210 leukemia in mice. Treatments prior to tumor inoculation were ineffective. Treatments from the third day post-tumor inoculation were most effective, and treatments every third day were more effective than were regimens involving more frequent treatments. IFN-alpha AD was effective in vivo against tumors formed from a line of L1210 cells resistant to IFN-alpha AD in cell cultures. These and other results indicate the importance and nature of indirect mechanisms of action for efficacy of interferons against tumors.
一种在大肠杆菌中产生的高度纯化的杂交人白细胞干扰素IFN-α AD,已被用于确定小鼠L1210白血病的最佳治疗条件。肿瘤接种前的治疗无效。肿瘤接种后第三天开始的治疗最有效,每三天治疗一次比更频繁治疗的方案更有效。IFN-α AD在体内对由细胞培养中对IFN-α AD耐药的L1210细胞系形成的肿瘤有效。这些及其他结果表明干扰素抗肿瘤疗效的间接作用机制的重要性和性质。